Arcadia Biosciences and DuPont Pioneer Achieve Milestone in the Development of High-Value Specialty Oil

ARA is an omega-6 fatty acid that, along with certain omega-3 fatty acids, plays a critical role in neural and visual development of infants. It is one of the most abundant fatty acids in the brain, and neurological health is reliant upon sufficient levels of ARA.

ARA is used as a functional ingredient in many infant nutrition products, and has been shown to provide developmental benefits similar to breastfeeding. Its use in nutritional products has been reviewed and supported by the U.S. Food and Drug Administration, the Food and Agriculture Organization of the United Nations and the World Health Organization. High ARA safflower plants will offer an alternative and more efficient source for the ingredient that will improve manufacturing economics and encourage wider use of ARA.

“The newly developed safflower oil could ultimately provide a renewable and sustainable source of this nutritionally important fatty acid. Since sunlight provides all the energy needed to make ARA in safflower seed oil, this production technique also is very cost-effective when compared with current commercial methods,” said Tony Kinney, research director, DuPont Pioneer.

“The achievement of this milestone further demonstrates Arcadia’s expertise in developing high-value nutritional oils leveraging our omega-6 platform,” said Raj Ketkar, CEO of Arcadia. “The development of ARA safflower oil will expand Arcadia’s nutritional oil offerings and will build on our experience in the development, regulatory management, production and marketing of these high-value products.”

Arcadia’s ARA safflower oil is in the late stages of product development. Regulatory approval would be sought prior to commercialization.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Arcadia’s ARA safflower oil. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: Arcadia’s and its partners’ ability to develop and market commercial products incorporating ARA safflower oil; the company’s compliance with laws and regulations that impact the company’s business, and changes to such laws and regulations; the company’s future capital requirements and ability to satisfy its capital needs; and the other risks set forth in the company’s filings with the Securities and Exchange Commission from time to time, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.